Biophytis Gains Momentum; bluebird bio Posts Mixed Results
- August 08th, 2023
- 236 views
Shares of Biophytis S.A. (Nasdaq: BPTS) surged over 10% in pre-market trading as the company secured a favorable opinion from Belgian authorities for its groundbreaking SARA-31 program.
This initiative marks the first-ever phase 3 study targeting sarcopenia, a neuromuscular ailment prevalent among the elderly, characterized by muscle strength decline and mobility loss, thereby impacting autonomy and life expectancy.
In pre-market, $BPTS was trading at $1.73, reflecting a substantial increase of $0.18 (+11.61%).
Meanwhile, bluebird bio, Inc. (Nasdaq: BLUE) has announced its second-quarter 2023 financial results, posting a loss of $0.67 per share. Although the loss was slightly better than the consensus estimate of $0.71 per share, the company's quarterly sales totaled $6.89 million, falling short of the analysts' projected revenue of $11.65 million for the period.
$BLUE was trading at $3.55 in pre-market, down $0.05 (-1.39%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
CSX, VinFast Auto, and Crown Castle's Earnings Preview
April 14th, 2024Earnings Spotlight: McCormick, TD SYNNEX, and GameStop Set to Report
March 23rd, 2024Upcoming Earnings: Adobe, Ulta Beauty, and Smartsheet Under the Lens
March 10th, 2024
Member Login